New Exclusive agreement

Headquartered in Singapore, MiRXES is a privately-held provider of life science research tools and developer of miRNA diagnostic tests.
 

It was founded by Professor Too Heng-Phon and his partners in 2014, with the vision of creating accurate, affordable, and actionable molecular diagnostic tests using advanced miRNA technologies to improve cancer screening processes. MiRXES's solutions identify cancer markers within microRNA to detect cancer in the early stages. Comparatively, current methods used to detect early-stage cancer such as blood tests, bioscopies, and endoscopies, are less efficient in screening for cancer.

Moving forward, MiRXES will expand the applicability of their solutions to include testing for gastric, lung, and breast cancer.

https://mirxes.com/